Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
334 Leser
Artikel bewerten:
(2)

Bank of Idaho Holding Company Reports Second Quarter 2024 Financial Results

IDAHO FALLS, ID / ACCESSWIRE / July 26, 2024 / Bank of Idaho Holding Company (the "Company") (OTCQX:BOID), the holding company for Bank of Idaho (the "Bank"), today announced its unaudited financial results for the quarter ended June 30, 2024. The Company reported consolidated net income of $2,586,000, or $0.58 per diluted share, for the second quarter of 2024 after recording a one-time tax expense of $425,000 in the second quarter related to the remeasurement to its deferred tax asset. Prior to the adjustment, earnings for the second quarter of 2024 were $3,011,000, or $0.68 per diluted share. This compares to $3,067,000, or $0.69 per diluted share, for the first quarter of 2024, and $2,274,000 or $0.51 per diluted share, for the second quarter of 2023.

"We are pleased to announce a strong second quarter with Bank of Idaho generating $4.6 million in pre-tax, pre-provision income and $0.68 adjusted earnings per share. Our commitment to prioritizing credit, pricing, and expense discipline continues to provide strong results for our shareholders," said Jeff Newgard, Chairman, President, and CEO of Bank of Idaho. "We are proud to serve dynamic geographic markets, which produce strong loan growth. We remain confident for the remainder of 2024 and beyond and intend to capitalize on emerging opportunities."

Quarterly Summary

  • Loans held for investment grew $47.1 million, or 5.1%, in Q2 2024 and increased $182.2 million, or 23.3%, from Q2 2023.

  • Total core deposits increased $75.9 million, or 8.0%, in Q2 2024 and were up $131.1 million, or 14.7%, from Q2 2023.

  • Pre-tax, pre-provision ("PTPP") net income was $4.57 million in Q2 2024, compared to $4.76 million in Q1 2024 and $3.66 million in Q2 2023.

  • Tangible book value ("TBV") per share increased to $25.90, or 3.0%, from $25.16 at Q1 2024, and increased 12.3% from $23.06 at Q2 2023. The increase in TBV is attributable to earnings and a decrease in unrealized losses within our securities portfolio.

Operating Results

Net income for the second quarter of 2024 was $2,586,000, or $0.58 per diluted share, compared to net income of $3,067,000, or $0.69 per diluted share, for Q1 2024, and $2,274,000, or $0.51 per diluted share, for the same quarter last year. The decrease from the prior quarter was the result of a one-time tax expense of $425,000 related to the remeasurement of the Company's deferred tax asset.

Net interest income for Q2 2024 was $12.6 million, an increase of $265,000, or 2.1%, from the prior quarter as interest income outpaced the increases in interest expense. Net interest income grew $790,000, or 6.7%, from the same period in the prior year.

Net interest margin for the second quarter of 2024 was 4.19% compared to 4.43% in the previous quarter and 4.82% for the same quarter last year. While there continues to be margin pressure from the Fed's restrictive rate policy and liquidity tightening mandate, we see healthy loan demand at attractive rates. While the cost of funding increases, the growth in earning assets at current market yields should outpace funding cost pressures.

Noninterest income, including net gains and losses, for Q2 2024 was $1,028,000, a decrease of $169,000, or 14.1%, from $1,197,000 in Q1 2024. The decrease was attributable to a $145,000 loss for a municipal security being called. Relative to the second quarter of 2023, noninterest income decreased $62,000, or 5.7%.

Noninterest expense of $9.06 million in Q2 2024 was an increase of $286,000, or 3.3%, from $8.77 million in Q1 2024 and a $182,000, or 2.0%, decrease from $9.24 million in Q2 2023. The increase from Q1 2024 was due to one-time personnel expenses of $75,000 and variable compensation of $90,000 due to increased loan production. The Company's efficiency ratio was 64.8% for Q2 2024, compared to 64.0% for Q1 2024, and 70.5% for Q2 2023.

Total assets were $1.29 billion as of June 30, 2024, an increase of $100.6 million, or 8.5%, from $1.19 billion at March 31, 2024. Second quarter 2024 balance sheet growth was driven by growth in portfolio loans of $47.1 million, or 5.1%. Loans were funded by the growth in deposits of $77.2 million, or 7.8%. Cash and cash equivalents increased $43.4 million along with an increase of $21.0 million in total borrowings.

Loans held for investment were $963.8 million as of June 30, 2024, an increase of $47.1 million, or 5.1%, from $916.7 million as of March 31, 2024, and an increase of $182.2 million, or 23.3%, from $781.6 million as of June 30, 2023. The increase in total loans from the previous quarter came from growth in all loan categories, the largest coming from an increase in the Bank's commercial and commercial real estate loans. We continue to see significant lending opportunities across our markets.

Deposits were $1,069.0 million as of June 30, 2024, up $77.2 million, or 7.8%, from the previous quarter, and up $175.3 million, or 19.6%, from the same quarter last year. The growth in our deposits is primarily in interest bearing products as customers continue to seek yield on their deposits. While we are successful in attracting deposits within our markets, deposits come at an elevated cost due competition from both bank and non-bank organizations. Noninterest bearing deposits represented 27% of total deposits and 28% of core deposits as of June 30, 2024, compared to 30% as of March 31, 2024, and 36% as of June 30, 2023.

Borrowings were $84.2 million as of June 30, 2024, which consisted of $24.6 million of Company subordinated debt, $24.6 million of BTFP advances, and $35.0 million of FHLB borrowings compared to $24.6 million of Company subordinated debt, $24.6 million of BTFP advances, and $14.0 million of FHLB borrowings in the previous quarter.

Asset quality remained strong in Q2 2024. Nonaccrual loans, excluding government guaranteed balances, totaled $2,351,000, or 0.24% of loans, as of June 30, 2024, compared to $2,194,000, or 0.19% of loans, as of March 31, 2024, and $269,000, or 0.03% of loans, as of June 30, 2023. The Company had no OREO for Q2 2024, Q1 2024, or Q2 2023.

The Allowance for Credit Losses ("ACL") totaled $11.8 million, or 1.23% of loans held for investment, as of June 30, 2024. The Company recorded $497,000 in provision for loan loss expense in the second quarter of 2024 compared to $645,000 in provision expense in the previous quarter, and $520,000 in provision in the second quarter of 2023. The Company recorded net charge-offs of $47,000 in the second quarter of 2024 bringing year-to-date net charge-offs to $126,000 or annualized 2.7 basis points of average loans.

Capital ratios of the Company and Bank continue to exceed the "well-capitalized" capital levels set by our respective regulators. As of June 30, 2024, the Bank's Tier 1 leverage ratio was 11.57% and the total risk-based capital ratio was 14.82%. As of June 30, 2024, the Company had tangible common equity (total stockholders' equity less intangible assets) of $114.8 million and tangible book value per share of $25.90. Tangible common equity increased $3.403 million in Q2 2024 due to quarterly earnings of $2.586 million and a $470,000 improvement to accumulated other comprehensive loss ("AOCL") related to decreased unrealized losses on our securities portfolio. The Company's tangible common equity to tangible assets ratio was 8.97% as of June 30, 2024, down from 9.42% in the previous quarter. There were no paid dividends during Q2 2024 or in any quarter presented.

About Bank of Idaho Holding Company

Bank of Idaho Holding Company is a bank holding company headquartered in Idaho Falls, Idaho. The Company's subsidiary, Bank of Idaho, is an independent commercial bank providing a range of business, personal, and mortgage banking products and services, as well as trust and wealth management services, to customers in Idaho and eastern Washington. The Company's common stock is traded on the OTCQX exchange under the symbol "BOID."

Non-GAAP Financial Measures

Some of the financial measures included in this press release are not measures of financial performance recognized in accordance with generally accepted accounting principles in the United States ("GAAP"). These non-GAAP financial measures include "efficiency ratio," "tangible common equity," "tangible common equity to tangible assets," "tangible book value per share," and "pre-tax pre-provision net income." Efficiency ratio is computed by dividing total noninterest expense, including intangible expense, by the sum of net interest income and noninterest income, including gains and losses. Tangible common equity is computed by subtracting goodwill and core deposit intangibles from total stockholders' equity. Tangible common equity to tangible assets is computed by dividing total assets, less goodwill and core deposit intangibles, by tangible common equity. Tangible book value per share is computed by dividing tangible common equity by common shares outstanding. Pre-tax, pre-provision net income is computed by adding provision for loan loss expense and income tax expense to net income. The Company believes these non-GAAP financial measures provide both management and investors with a more complete understanding of the Company's financial position and performance. These non-GAAP financial measures are supplemental and are not a substitute for any analysis based on GAAP financial measures. Not all companies use the same calculation of these measures; therefore, this presentation may not be comparable to other similarly titled measures as presented by other companies.

Forward-Looking Statements

This press release contains, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements preceded by, followed by, or that include the words "may," "could," "should," "would," "believe," "anticipate," "estimate," "expect," "intend," "plan," "projects," "outlook" or similar expressions. These statements are based upon the current belief and expectations of the Company's management team and are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate. Therefore, the Company can give no assurance that the results contemplated in the forward-looking statements will be realized. The inclusion of this forward-looking information should not be construed as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved.

All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. The Company does not undertake any obligation to update any forward-looking statement to reflect circumstances or events that occur after the date the forward-looking statements are made, except as required by law.

###

CONTACT: Matt Borud, Bank of Idaho
Phone: 208.412.2322
Email: mattborud@bankofidaho.net

SOURCE: Bank Of Idaho Holding Co



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.